DCP Midstream to Participate in the 2019 Wells Fargo Midstream and Utility Symposium

DENVER, Dec. 04, 2019 (GLOBE NEWSWIRE) — DCP Midstream, LP (NYSE: DCP) announced that Wouter van Kempen, chairman, president and chief executive officer, and Sean O’Brien, group vice president and chief financial officer, will conduct a series of one-on-one and group meetings with investment community representatives at the 2019 Wells Fargo Midstream and Utility Symposium in New York on December 11, 2019. The materials used at this conference will be posted on the Investors section of DCP Midstream’s website at www.dcpmidstream.com on December 10, 2019.

ABOUT DCP MIDSTREAM, LP

DCP Midstream, LP (NYSE: DCP) is a Fortune 500 midstream master limited partnership headquartered in Denver, Colorado, with a diversified portfolio of gathering, processing, logistics and marketing assets. DCP is one of the largest natural gas liquids producers and marketers and one of the largest natural gas processors in the U.S. The owner of DCP’s general partner is a joint venture between Enbridge and Phillips 66. For more information, visit the DCP Midstream, LP website at www.dcpmidstream.com.

DCP Investor and Media Relations

Sarah Sandberg
(303) 605-1626

Norwegian Cruise Line Holdings Ltd. Celebrates the 96th Annual New York Stock Exchange Tree Lighting With Virtual Reality Showcase and Cruise Giveaways

Virtual Reality Experience to Showcase Silver Cove, the New Expansion of Company’s Private Island in the Bahamas, Great Stirrup Cay

Company to Offer Event Attendees a Chance to Win a Cruise on its Newest, Most Innovative Ship, Norwegian Encore

MIAMI, Dec. 04, 2019 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (“Norwegian”) (NYSE: NCLH), a leading global cruise company which operates the Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises brands, today announced its participation in the 96th Annual New York Stock Exchange Tree Lighting event on December 5th. During the event the Company will feature a virtual reality experience that will transport attendees from the cold winter weather in New York City to the tropical white sandy beaches of Norwegian’s luxurious private island in the Bahamas, Great Stirrup Cay. The experiences will showcase the island and its newly opened private luxury enclave, Silver Cove. The Company will also offer event attendees a chance to win one of five cruises on its newest and most innovative ship, Norwegian Encore.

“We are kicking off the holiday season right with the celebration of the 96th Annual New York Stock Exchange Tree Lighting,” said Frank Del Rio, president and chief executive officer of Norwegian Cruise Line Holdings Ltd. “What better way to spread holiday cheer than to offer the chance to win a cruise on our newest and best-in-class ship, Norwegian Encore, and an opportunity to virtually experience paradise at our luxurious private Bahamian island.”

The recently unveiled exclusive oceanfront resort-style destination, Silver Cove, is the latest enhancement designed to elevate the guest experience at Norwegian’s 270-acre tropical oasis. The new oceanfront lagoon area includes private beachfront villas, a Mandara Spa with beachfront treatments as well as the exclusive Moët & Chandon Bar and upscale Silver Cove Restaurant and Bar. The 38 luxury air-conditioned villas range from studios to larger one-and-two-bedroom villas, all of which include private bathroom, daybed, club chairs, televisions with on-demand entertainment, outdoor patio and lounge seating, retractable glass walls providing unobstructed views and access to the private beachfront lagoon.

Great Stirrup Cay continues to be one of the line’s highest guest-rated ports featuring over 1,500 feet of accessible beachfront with white sand beaches; over 50 cabana and villa options; an array of fun-filled shore excursions including a new over water zipline experience that extends nearly 3,000 feet in length; and a dozen on-island food and beverage offerings. For Norwegian Encore’s press kit, including Silver Cove at Great Stirrup Cay assets, click here.

During the tree lighting event, event attendees can participate in a trivia contest and five event attendees will win their choice of a 7-Day cruise for two to the Caribbean or Bermuda in a balcony stateroom on Norwegian Encore, the Company’s newest, most innovative ship. For a chance to win, event attendees must visit Norwegian’s table during the tree lighting event for more information.

The NYSE Christmas tree has been a Downtown New York tradition since 1923, and is one of New York City’s oldest traditions, celebrating its 96th year. Initially the Exchange celebrated the holiday on its Trading Floor, but in 1923 began erecting a Christmas tree in front of its façade on Broad Street to celebrate with a public tree lighting for New Yorkers and visitors to the Big Apple.

The date coincides with the national tree lighting tradition and the completion of a fully developed electrical grid in Manhattan. On December 24, 1923, President Coolidge presided over the first national tree lighting which was organized to promote the use of electricity and electric Christmas lights as a safe alternative to candles on trees. It was a joint venture between the US Government and the electric industry. Since its founding, the NYSE has marked the Christmas Season as both a time of celebration and giving.


About Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) is a leading global cruise company which operates the Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises brands. With a combined fleet of 27 ships with approximately 58,400 berths, these brands offer itineraries to more than 450 destinations worldwide. The Company will introduce ten additional ships through 2027.

Investor Relations & Media Contact

Andrea DeMarco
(305) 468-2339
InvestorRelations@nclcorp.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/58461e55-c0a8-4f15-ade7-fb76cb725dc0

https://www.globenewswire.com/NewsRoom/AttachmentNg/8fa7d13c-971b-4d75-843e-ca2669f2f7bb

https://www.globenewswire.com/NewsRoom/AttachmentNg/5bf5700c-af6b-4345-8b2e-a5fb42a174da

Micron Publishes Fiscal 2019 Diversity, Equality and Inclusion Report

Second Annual Report Highlights Increasing Representation of Underrepresented Groups and Building a Culture of Inclusion

BOISE, Idaho, Dec. 04, 2019 (GLOBE NEWSWIRE) — Micron Technology, Inc. (Nasdaq: MU), today announced the publication of its second annual diversity, equality and inclusion report. The report is part of the company’s continued efforts to build a diverse workforce and inclusive culture. It demonstrates Micron’s progress in several key areas, including women’s representation, pay equity and growth of employee resource groups (ERGs).

“Micron is pleased to announce the publication of our Diversity, Equality and Inclusion FY19 Annual Report, demonstrating our commitment to creating an environment where all team members can bring their authentic selves to work and contribute ideas that drive business success,” said Micron Vice President of Diversity, Equality and Inclusion Sharawn Connors. “Micron believes that collaboration across our diverse workforce is the key to unlocking strength and innovation, and we are passionate about building a culture of inclusion where all team members are seen, heard, valued and respected.”

The Micron Diversity, Equality and Inclusion FY19 Annual Report provides a baseline for tracking the company’s progress, examining a variety of factors, including race/ethnicity, gender, job roles, philanthropy and compensation.

The report contains a number of highlights:

  • Dimensions of Diversity

    • The expansion of Micron’s ERGs has been instrumental in creating an inclusive environment for everyone. The company added three new ERGs focused on the following groups: Black/African American team members, tenured and experienced team members and team members with disabilities. ERG membership grew by 72%, with eight ERGs and 38 global chapters.
    • Micron launched its first ERG for people with disabilities, called Capable. Providing quality jobs and career advancement opportunities for people with disabilities is a strong focus at the company’s Japan, Taiwan, Europe and U.S. sites.
    • Micron sponsored Pride parades in the U.S. — Boise, Idaho, and Washington D.C. — and launched an Inclusion Allies Coalition online-learning module.
  • Women’s Representation Globally

    • Micron welcomed two women to its board of directors: Mary Pat McCarthy and MaryAnn Wright. As a result, women now make up 25% of Micron’s board.
    • The percentage of female vice presidents at Micron nearly doubled, and the percentage of women in senior leadership increased from 10.4% to 13.5%.
    • In FY19, Micron launched the Women Innovate (WIN) program to increase female participation in Micron’s patent program via mentorship and to promote collaboration and innovation. 
  • Pay Equity

    • Micron is committed to providing equal salary to men and women in similar roles in all our worldwide locations. In support of Micron’s ongoing commitment to pay equity, we regularly conduct proactive pay audits. As we closed FY19, we invested $830,000 to address differences in pay.
    • Micron continues to enhance compensation policies and practices and has implemented more stringent compensation guidelines and in-depth reviews of off-cycle increases.

Micron is pleased to be recognized as one of Forbes Best Employers for Diversity in 2019. Forbes’ anonymous survey asked over 50,000 participants to rank their organizations on fair and equal treatment of workers across the following categories: age, gender, ethnicity, disability and sexual orientation.

Micron’s approach to diversity, equality and inclusion aims to create an environment where all Micron team members have opportunities to grow, contribute and advance. The full Micron Diversity, Equality and Inclusion FY19 Annual Report can be found at http://www.micron.com/dei.

About Micron Technology, Inc.

We are an industry leader in innovative memory and storage solutions. Through our global brands — Micron®, Crucial®, and Ballistix® — our broad portfolio of high-performance memory and storage technologies, including DRAM, NAND, NOR Flash and 3D XPoint™ memory, is transforming how the world uses information to enrich life. Backed by 40 years of technology leadership, our memory and storage solutions enable disruptive trends, including artificial intelligence, machine learning and autonomous vehicles, in key market segments like data center, networking, automotive, industrial, mobile, graphics and client. Our common stock is traded on the Nasdaq under the MU symbol. To learn more about Micron Technology, Inc., visit micron.com.

© 2019 Micron Technology, Inc. All rights reserved. Information, products, and/or specifications are subject to change without notice. Micron, the Micron logo, and all other Micron trademarks are the property of Micron Technology, Inc. All other trademarks are the property of their respective owners.

Micron Media Relations Contact
Erica Pompen
Micron Technology, Inc.
+1 (408) 834-1873
epompen@micron.com

Micron Investor Relations Contact
Farhan Ahmad 
Micron Technology, Inc. 
+1 (408) 834-1927
farhanahmad@micron.com

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abeona, AZZ, Under Armour, and UP Fintech and Encourages Investors to Contact the Firm

NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Abeona Therapeutics, Inc. (NASDAQ: ABEO), AZZ, Inc. (NYSE: AZZ), Under Armour, Inc. (NYSE: UA, UAA), and UP Fintech Holding Limited (NASDAQ: TIGR). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Abeona Therapeutics, Inc. (NASDAQ: ABEO)

Class Period: May 31, 2018 to September 23, 2019

Lead Plaintiff Deadline: January 2, 2019

EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (“RDEB”) is one of Abeona’s lead programs.  From preliminary clinical data and expert input, the Company expected EB-101 to be a potential treatment choice for most wounds, and believes it is currently the only product candidate being evaluated as a treatment for larger wounds.

Results from a completed Phase I/​II study that enrolled seven patients with chronic RDEB wounds at Stanford University purportedly showed that EB-101 was well-tolerated and resulted in significant and durable wound healing. 

Abeona expected to initiate a pivotal clinical trial evaluating the potential of EB-101 for the treatment of RDEB in the middle of 2019.  The so-called VITAL Study would be a multicenter, randomized, Phase III clinical trial assessing ten to fifteen patients treated with EB-101.

On September 23, 2019, Abeona issued a press release announcing receipt of a clinical hold letter from the FDA, “clarifying that the FDA will not provide approval for the Company to begin its planned Phase 3 clinical trial for EB-101 [a/k/a, the VITAL Study] until it submits to the FDA additional data points on transport stability of EB-101 to clinical sites” (the “September 2019 Press Release”).  The September 2019 Press Release also disclosed that Abeona had been working with the FDA for at least a year to address issues with the Company’s CMC.

On this news, Abeona’s stock price fell $0.39 per share, or 11.96%, to close at $2.87 per share on September 23, 2019.

The complaint, filed on November 1, 2019, alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies.  Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Abeona’s Chemical, Manufacturing and Controls (“CMC”) and internal controls and procedures and/or compliance policies were inadequate; (ii) as a result, the Company failed to provide sufficient data points on the transport stability of EB-101 to clinical sites, or else such transport stability was insufficient; (iii) consequently, it was foreseeable that the U.S. Food and Drug Administration (“FDA”) would reject approval for the start of the VITAL Study until such issues were addressed; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

For more information on the Abeona class action go to: https://bespc.com/abeo

Azz, Inc. (NYSE: AZZ)

Class Period: July 3, 2018 to October 8, 2018

Lead Plaintiff Deadline: January 3, 2020

On May 17, 2019, AZZ disclosed a weakness in its internal control over financial reporting related to preparation and review of revenue reconciliations after adopting a new revenue recognition standard.

On May 20, 2019 AZZ announced that it had replaced its independent auditor, BDO US, LLP, with Grant Thornton LLP.

On this news, the Company’s stock price fell $1.21, nearly 3%, to close at $43.35 per share on May 20, 2019.

On October 8, 2019, AZZ delayed its second quarter 2020 financial results “to allow the Company additional time to complete the review of the Form 10-Q for its fiscal year 2020 second quarter ended August 31, 2019.”

On this news, the Company’s stock price fell $5.89, nearly 14%, to close at $37.12 per share on October 8, 2019.

Finally, on October 25, 2019, AZZ announced that its Chief Accounting Officer “will leave the Company effective October 31, 2019.”

The complaint, filed on November 4, 2019, alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company’s internal controls over financial reporting were not effective; (2) that the Company improperly implemented ASC 606 which resulted in improper revenue reconciliations; and (3) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the Azz class action go to: https://bespc.com/azz-2

Under Armour, Inc. (NYSE: UA, UAA)

Class Period: August 3, 2016 to November 1, 2019

Lead Plaintiff Deadline: January 6, 2020

On November 3, 2019, the Wall Street Journal reported on U.S. Department of Justice and Securities and Exchange Commission investigations into Under Armour’s accounting practices and related disclosures. The article, entitled “Under Armour Is Subject of Federal Accounting Probes,” noted that the investigations are concerning whether Under Armour shifted sales from quarter to quarter to appear healthier. That same day, the Company confirmed to the Wall Street Journal that it had been cooperating with the U.S. Department of Justice and Securities and Exchange Commission since July 2017.

On this news, Class C shares of Under Armour (UA) fell $3.47 per share or 18.35% to close at $15.44 per share and Class A shares of Under Armour (UAA) fell $4.00 per share or 18.92% to close at $17.14 per share on November 4, 2019, damaging investors.

The complaint, filed on November 6, 2019, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Under Armour shifted sales from quarter to quarter to appear healthier, including to keep pace with their long-running year-over-year 20% net revenue growth; (2) the Company had been under investigation by and cooperating with the U.S. Department of Justice and U.S. Securities and Exchange Commission since at least July 2017; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

For more information on the Under Armour class action go to: https://bespc.com/underarmour

UP Fintech Holding Limited (NASDAQ: TIGR)

Class Period: Securities purchased pursuant and/or traceable to the Company’s initial public offering conducted on or about March 20, 2019 (the “IPO” or “Offering”) and/or purchased between March 20, 2019 and May 16, 2019 (the “Class Period”).

Lead Plaintiff Deadline: January 6, 2020

On February 22, 2019, Fintech filed a registration statement on Form F-1 with the SEC in connection with the IPO, which was declared effective by the SEC on March 19, 2019 (the “Registration Statement”). The Registration Statement was filed with respect to the underlying Class A ordinary shares represented by the ADSs to be sold in the IPO.

On March 20, 2019, Fintech filed a prospectus for the IPO  (the “Prospectus”), which incorporated and formed part of the Registration Statement (collectively, the “Offering Documents”). That same day, Fintech announced the pricing of its IPO of 13 million ADSs, each representing fifteen Class A ordinary shares of the Company, at $8.00 per ADS. The ADSs began trading the same day on the NASDAQ under the symbol “TIGR.” Fintech raised $104 million in proceeds from the IPO.

The complaint, filed on November 6, 2019, alleges that the Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, in the Offering Documents and during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) Fintech was experiencing a material decrease in commissions because of a negative trend related to risk averse investors in the market; (ii) Fintech was unable to absorb costs associated with the rapid growth of its business and its status as a publicly listed company on a U.S. exchange; (iii) Fintech was incurring significant additional expenses related to, inter alia, employee headcount and employee compensation and benefits; (iv) all of the foregoing had led to Fintech significantly increasing operating costs and expenses; and (v) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein, and the Company’s Class Period statements were likewise materially false and/or misleading.

On May 17, 2019, during pre-market hours, Fintech issued a press release announcing its unaudited first quarter 2019 financial results—the Company’s first quarterly earnings announcement following the IPO (the “1Q19 Press Release”). In that press release, Fintech disclosed a 4.1% decrease in commissions, noting that “[i]nvestors were relatively risk averse at beginning of this year which leads to moderated trading activities and a slight decrease in trading commission.” The 1Q19 Press Release also disclosed, among other issues, that Fintech’s operating costs and expenses and net loss attributable to the Company had begun to skyrocket as a result of increases in expenses related to employee headcount, employee compensation and benefits, and office space and leasehold improvements, as well as rapid customer growth, expanded market data usage for its customers, and additional professional expenses as a listed company.

Specifically, with respect to Fintech’s drastically increasing operating costs and expenses and net loss attributable to the Company, the 1Q19 Press Release disclosed that total operating costs and expenses for the first quarter of 2019 increased by 36.4% to $14.0 million from $10.3 million in the first quarter of 2018, and that employee compensation and benefits increased by 60.8% from $4.9 million in the first quarter of 2018 to $7.8 million in the first quarter of 2019.

On this news, Fintech’s ADS price fell $1.21 per share, or 17.34%, to close at $5.77 per share on May 17, 2019.

For more information on the UP Fintech class action go to: https://bespc.com/tigr

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes. 

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

 

SYNTHESIS ENERGY SYSTEMS ANNOUNCES COMPLETION OF BATCHFIRE PRE-EMPTIVE RIGHTS PROCESS


Upon successful conclusion of the merger with Australian Future Energy, SES will increase its ownership in Batchfire from 7.4% to 37.2%

Highlights:

  • 37.2% of Batchfire shareholders accepted SES’s offer to acquire their shares, exceeding the 25% minimum participation requirement
  • Batchfire owns and operates one of Australia’s largest and lowest-cost thermal coal mines
  • Achieving the additional ownership in Batchfire is part of the merger transactions underway with Australian Future Energy
  • The increased Batchfire ownership is expected to strengthen the Company’s operating results and balance sheet in the future

HOUSTON, Dec. 04, 2019 (GLOBE NEWSWIRE) — Synthesis Energy Systems, Inc. (SES) (Nasdaq: SES) today announced the finalization of the pre-emptive rights process that was required to be undertaken, pursuant to the constitution of Batchfire Resources Pty Ltd (Batchfire), in respect of the Batchfire shareholders who had entered into a Share Exchange Agreement with SES, accepting SES’s offer to acquire their shares in Batchfire, which is the owner of the Callide Mine in Queensland, Australia. The other shareholders in Batchfire elected not to exercise their pre-emptive rights over these shares.

SES made the offer to acquire the issued capital of Batchfire via the proposed issuance and exchange of one share of SES common stock for each ten ordinary shares of Batchfire, in connection with SES’s entry into the definitive Merger Agreement with Brisbane-based Australian Future Energy Pty Ltd (AFE), announced on October 10, 2019.

The Batchfire share exchange will increase SES’s Batchfire ownership to 37.2% from its current 7.4% holding, subject to conditions specified in the Share Exchange Agreements being satisfied and the completion of the proposed merger transactions with AFE.

The final transfer of the Batchfire shares to SES is subject to the receipt of final stakeholder consents as outlined in the filings that were completed on October 10, 2019. For additional information relating to Batchfire, and the Callide Mine and its key customers, see SES’s news release, Synthesis Energy Systems to Acquire Australian Future Energy (October 10, 2019).

Robert Rigdon, SES’s CEO, commented: “This is a good result for SES, exceeding our minimum acceptance level of 25% when the offer was made. We believe the acquisition of additional ownership in Batchfire and this important merger transaction with AFE have the potential to bring growth and value to SES’s shareholders and debenture holders. SES is progressing the additional required filings and processes necessary for the closing of the merger.”

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. All statements other than statements of historical fact are forward-looking statements and are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are the possibility that the companies may be unable to obtain stockholder approval or satisfy the other conditions to closing, the ability of Batchfire Resources Pty Ltd, and Australian Future Energy Pty Ltd management to successfully grow and develop their Australian assets and operations, including Callide, Pentland, and the Gladstone Energy and Ammonia Project; the ability of Batchfire to produce earnings and pay dividends; the ability of SES EnCoal Energy sp. z o. o. management to successfully grow and develop projects, assets and operations in Poland; our ability to raise additional capital; our indebtedness and the amount of cash required to service our indebtedness; our ability to develop our power business unit and our other business verticals, including DRI steel, through our marketing arrangement with Midrex Technologies; our ability to successfully develop our licensing business; the ability of our project with Yima to produce earnings and pay dividends; the economic conditions of countries where we are operating; events or circumstances which result in an impairment of our assets; our ability to reduce operating costs; our ability to make distributions and repatriate earnings from our Chinese operations; our ability to maintain our listing on The Nasdaq Stock Market; our ability to successfully commercialize our technology at a larger scale and higher pressures; commodity prices, including in particular natural gas, crude oil, methanol and power; the availability and terms of financing; our customers’ and/or our ability to obtain the necessary approvals and permits for future projects; our ability to estimate the sufficiency of existing capital resources; the sufficiency of internal controls and procedures; and our results of operations in countries outside of the U.S., where we are continuing to pursue and develop projects. Although we believe that in making such forward-looking statements our expectations are based upon reasonable assumptions, such statements may be influenced by factors that could cause actual outcomes and results to be materially different from those projected by us. We cannot assure you that the assumptions upon which such forward-looking statements are based will prove to be correct. Please refer to our latest Form 10-K available on our website at http://www.synthesisenergy.com.

Additional Information about the Transaction

In connection with the proposed transaction, SES intends to file with the SEC a registration statement on Form S-4 that will include a proxy statement of SES that also constitutes a prospectus of SES relating to the Common Stock to be issued pursuant to the Merger. The proxy statement/prospectus will include important information about both SES and AFE. SES also plans to file other relevant documents with the SEC regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO CAREFULLY READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SES, AFE AND THE PROPOSED TRANSACTION. Investors and security holders may obtain these documents when available free of charge at the SEC’s website at www.sec.gov. In addition, the documents filed with the SEC by SES can be obtained free of charge from SES’s website at www.synthesisenergysystems.com.

Participants in Solicitation

SES and its executive officers and directors may be deemed to be participants in the solicitation of proxies from the shareholders of SES in respect of the proposed transaction. Information regarding SES’s directors and executive officers is available in its annual report on Form 10-K for the year ended June 30, 2018, which was filed with the SEC on November 14, 2018, and its proxy statement for its 2018 annual meeting of shareholders, which was filed with the SEC on April 29, 2019. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available.

About Batchfire Resources Pty Ltd

Batchfire Resources Pty Ltd is a privately owned Australian company, based in Brisbane, Queensland that operates the Callide Coal Mine. Callide is an open-cut operation located 120 km southwest of Gladstone and 20 km northeast of the thriving regional township of Biloela, in Central Queensland. The mine has operated since 1944 producing low sulphur, sub-bituminous thermal coal primarily for domestic power generation and alumina refining. Under the ownership of Batchfire Resources since October 2016, the mine is continuing to meet the quality and performance benchmarks sought by its domestic customers while looking to expand export opportunities. The Callide mining tenure extends across 180 square kilometres and contains an estimated coal resource of up to 1.7 billion tonnes.

Contact:


MDC Group


Investor Relations:
David Castaneda
Arsen Mugurdumov
414.351.9758
IR@synthesisenergy.com


Media Relations:


Susan Roush
805.624.7624
PR@synthesisenergy.com


Australian Future Energy


Mr. Kerry Parker
Chief Executive Officer
+61 417 731 014
k.parker@ausfutureenergy.com.au

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Quad/Graphics, Tandy Leather, Resideo Technologies, and Yunji and Encourages Investors to Contact the Firm

NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Quad/Graphics, Inc. (NYSE: QUAD), Tandy Leather Factory, Inc. (NASDAQ: TLF), Resideo Technologies, Inc. (NYSE: REZI), and Yunji, Inc. (NASDAQ: YJ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Quad/Graphics, Inc. (NYSE: QUAD)

Class Period: February 21, 2018 to October 29, 2019

Lead Plaintiff Deadline: January 6, 2020

On October 29, 2019, the Company slashed its quarterly dividend to $0.15 per share, announced plans to divest its book business, and reported third quarter 2019 financial results. Analysts were “absolutely shocked by these developments given the confidence management had just three months ago.”

On this news, the Company’s stock price fell $6.42 per share, or nearly 57%, to close at $4.85 per share on October 30, 2019.

The complaint, filed on November 7, 2019, alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company’s book business in United States was underperforming; (2) that, as a result, the Company was likely to divest its book business; (3) that the Company was unreasonably vulnerable to decreases in market prices; (4) that, to remain financially flexible while market prices decreased, the Company was likely to cut its quarterly dividend and expand its cost reduction programs; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

For more information on the Quad/Graphics class action go to: https://bespc.com/quad

Tandy Leather Factory, Inc. (NASDAQ: TLF)

Class Period: March 7, 2018 to August 25, 2019

Lead Plaintiff Deadline: January 6, 2020

On August 13, 2019, the Company disclosed that its Audit Committee was investigating “certain aspects of the Company’s methods of valuation and expensing of costs of inventory and related issues regarding the Company’s business and operations.”

On this news, the Company’s share price fell $0.55 per share, or over 10%, over two consecutive trading sessions to close at $4.90 per share on August 15, 2019, thereby injuring investors.

Then, on August 15, 2019, the Company disclosed that it was unable to timely file the Company’s quarterly report for the period ended June 30, 2019 due to the Audit Committee’s investigation.

On this news, the Company’s share price fell $0.40 per share, or over 8%, to close at $4.50 per share on August 16, 2019.

Finally, on October 18, 2019, the Company revealed that certain financial statements should no longer be relied upon, citing “misstatements primarily relating to the Company’s methods of valuation and expensing of costs of inventory and related issues.” It also disclosed that its Chief Financial Officer and Treasurer, Tina Castillo, had resigned from her positions.

The complaint, filed on November 7, 2019, alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that certain costs of inventory had been improperly valued and expensed; (2) that, as a result, the Company’s financial results for certain periods were misstated; (3) that the Company lacked effective internal control over financial reporting; (4) that there was a material weakness in the Company’s internal control over financial reporting; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

For more information on the Tandy Leather class action go to: https://bespc.com/tlf

Resideo Technologies, Inc. (NYSE: REZI)

Class Period: October 10, 2018 to October 22, 2019

Lead Plaintiff Deadline: January 7, 2019

The Company was formed through a spin-off from Honeywell International Inc. on October 29, 2018. The Company began trading under the ticker symbol “REZI” on the New York Stock Exchange (“NYSE”) on October 29, 2018.

The complaint, filed on November 8, 2019, alleges that during the Class Period, Resideo continued to assure investors that the Company was poised to meet its 2018 guidance at the high end of its forecasted range, and more importantly, for 2019 the Company would achieve 4%+ organic growth and ~13% adjusted EBITDA margin. Further, while the Company acknowledged it had experienced operational disruptions (primarily administrative) in connection with the spin-off, defendants repeatedly assured investors that any negative effects of the spin-off were largely “behind [them]” or minimizing and reiterated their fiscal year (“FY”) 2019 guidance for the Company, stating as late as August 8, 2019 that the Company’s performance to date put it on track to make its FY19 revenue guidance. Each of these representations was materially false and misleading when made because defendants failed to disclose the following true facts, which were known to defendants or recklessly disregarded by them: (a) the negative operational effects of the spin-off were more substantial and persistent than disclosed and had negatively affected the Company’s product sales, supply chain, and gross margins, putting Resideo’s FY19 financial forecasts at risk; and (b) as a result of the foregoing, the Company’s financial guidance lacked a reasonable basis and the Company was not on track to make its FY19 guidance as claimed. As a result of defendants’ material misrepresentations and omissions, Resideo stock traded at artificially inflated prices of more than $26 per share during the Class Period.

Then, on October 22, 2019, Resideo shocked investors when it issued its preliminary financial results for the third quarter of 2019, announcing that it had missed revenue and earnings targets and was lowering its recently reaffirmed revenue outlook for FY19 by $80 million.

Also on October 22, 2019, the Company announced that defendant Ragan, the Company’s CFO, would be leaving as of November 6, 2019.

Following these disclosures and a significant reduction in the Company’s outlook for free cash flow, Resideo’s stock price declined more than 40%, from a close of $15.23 per share on October 22, 2019 to a close of $9.50 per share on October 23, 2019.

For more information on the Resideo class action go to: https://bespc.com/rezi

Yunji, Inc. (NASDAQ: YJ)

Class Period: Securities purchased pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s May 2019 initial public offering (“IPO” or the “Offering”).

Lead Plaintiff Deadline: January 13, 2020

On May 3, 2019, the Company held its IPO in which it sold 11,217,447 shares for $11.00 per share.

On August 22, 2019, the Company disclosed a supply chain restructuring that shifted part of its merchandise sales to its marketplace platform, resulting in a year-over-year decrease in total revenues for second quarter 2019.

On this news, the Company’s share price fell $1.21, or nearly 11%, to close at $9.39 per share on August 22, 2019. Yunji’s share price continued to decline by $3.34, or over 35%, over the next three consecutive trading sessions to close at $6.05 per share on August 27, 2019.

By the time this class action was filed, Yunji’s shares were trading as low as $4.40 per share, a nearly 60% decline from the $11 per share IPO price.

The complaint, filed on November 12, 2019, alleges that the Registration Statement was false and misleading and omitted to state material adverse facts. Specifically, Defendants failed to disclose to investors: (1) that the Company was shifting certain of its sales to its marketplace platform; (2) that this supply chain restructuring was likely to disrupt Yunji’s relationships with suppliers; (3) that this supply chain restructuring was likely to have an adverse impact on the Company’s financial results; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

For more information on the Yunji class action go to: https://bespc.com/yj

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes. 

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities

– Prioritizing Development of Reloxaliase for Patients with Enteric Hyperoxaluria (EH) –

– Plan to Re-Engage with U.S. Food and Drug Administration (FDA) to Evaluate Opportunities to Streamline URIROX-2, Second Pivotal Phase 3 Trial of Reloxaliase in EH –

– Implementing Measures to Reduce Expenses and Preserve Capital for Reloxaliase Programs –

NEWTON, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) — Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced updates on its clinical development programs for reloxaliase, a potential first-in-class, non-absorbed, orally administered enzyme for the treatment of severe hyperoxaluria, and several initiatives to realign resources to support the continued development of reloxaliase for patients with enteric hyperoxaluria (EH).

Following positive topline results from URIROX-1 and further analysis of the data from the trial, Allena plans to re-engage with the FDA, with the request to discuss measures to potentially streamline its ongoing URIROX program through modifications to the adaptive URIROX-2 trial design. These enhancements could potentially include reducing the target enrollment in URIROX-2, conducting an earlier interim analysis of the data from URIROX-2, and modifying the requirements for filing for accelerated approval of the initial reloxaliase Biologics Licensing Application (BLA). The company expects to meet with the FDA in early 2020 and to provide an update on the final design and timing of the URIROX-2 study as it evolves.

“We continue to be encouraged by the pivotal Phase 3 URIROX-1 results and are committed to advancing reloxaliase as the first potential approved treatment for patients with EH,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “Reloxaliase achieved its primary endpoint in URIROX-1, demonstrating a statistically significant and clinically meaningful reduction in urinary oxalate (UOx). Based on the positive feedback that we continue to receive from key opinion leaders and clinicians and the severity of the condition in our trial population, we are confident that reloxaliase has the potential to alter the treatment landscape for patients with EH, and offer treating physicians an important new tool for combating the toxic accumulation of excess oxalate in patients with gastrointestinal (GI) disorders. We look forward to initiating discussions with the FDA in the near-term, as we consider opportunities to streamline the URIROX-2 program and expeditiously deliver reloxaliase to patients.”

Allena is implementing several measures in order to preserve capital and focus its resources on its reloxaliase programs, while maintaining key product development and corporate capabilities:

  • The company will limit the opening of new trial sites for its ongoing URIROX-2 trial and continue to enroll patients at existing sites, until further clarity from the FDA is received regarding potential changes to the URIROX program.
  • The company will delay additional planned investments in manufacturing.
  • The company will implement a reduction in its workforce that will lead to an approximately 30 percent reduction in salary and related compensation expenses.

Allena also remains focused on completing its ongoing Study 206 in patients with EH and advanced chronic kidney disease (CKD). Based on the results of the study and the severity of the condition, the company plans to interact with regulatory agencies in the first quarter of 2020 to discuss the registrational path, including expedited options, for reloxaliase in high-risk EH patients with CKD. Additionally, Allena remains on track to file an investigational new drug (IND) application for ALLN-346, a novel urate-degrading enzyme, this quarter, though first-in-human studies will be pursued only once additional financial resources are secured.

With these measures in place, Allena expects that its current cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2020.  The company also continues to explore a range of potential financial alternatives to support the development of reloxaliase, including potential financing transactions and business development partnerships.

Dr. Brenner added: “We remain conscious of the additional resources we need to advance reloxaliase through our URIROX program. To that end, we have made the difficult decision to realign our investments and internal resources to provide us with resources to enable us to focus on, and execute against, our strategy of delivering reloxaliase for the treatment of patients across the spectrum of EH. Unfortunately, this will impact a number of our highly talented and dedicated employees. We are incredibly grateful to those who are affected by this decision, and deeply appreciative of all of their hard work to support our development of novel therapies for patients with rare and severe metabolic disorders.”

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the topline data from the URIROX-1 clinical trial, Allena’s ongoing review of these data and implications for the future clinical, regulatory and commercial potential of reloxaliase, statements regarding plans to reengage with the FDA, statements regarding future plans for the URIROX-2 clinical trial, statements regarding Allena’s development of ALLN-346, including the expected timing of its IND filing, and statements concerning Allena’s cash position, potential cost savings, the sufficiency of cash to fund operations and ability to complete a financing transaction and/or business development partnership.  In addition, it should be noted that additional capital will be required to fund operations, including completion of the planned URIROX-2 clinical trial, which capital may not be available to Allena on terms that are acceptable to it, if at all. If adequate funds are not available on a timely basis, Allena may be required to amend, delay, limit, reduce or terminate one or more of its ongoing or planned clinical trials of its product candidates. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that Allena’s clinical and regulatory strategy for reloxaliase may evolve following further review of the topline data from the URIROX-1 clinical trial and Study 206, including without limitation, modifications or termination of the planned URIROX-2 clinical trial; the risk that the results of the URIROX-1 clinical trial may not be replicated in the URIROX-2 or other clinical trials of reloxaliase; the risk that the reduction in 24-hour UOx excretion observed in the placebo arm of the URIROX-1 trial may be observed in the URIROX-2 or other clinical trials of reloxaliase, which may have a negative impact on Allena’s ability to secure regulatory approval for this product candidate; the risk that results of earlier studies, or interim results, may not be predictive of future clinical trial results, and planned and ongoing studies may not establish an adequate safety or efficacy profile for reloxaliase to support regulatory approval or the use of the accelerated approval regulatory pathway; risks related to Allena’s ability to utilize the accelerated approval pathway for reloxaliase, including the risk that available data at the time of any sample size re-estimation or interim analysis conducted during the URIROX-2 trial may not be sufficient to demonstrate an increased probability of kidney stone events in patients with enteric hyperoxaluria and increasing UOx levels; the risk that the FDA may require that Allena increase the sample size or duration of treatment following the sample size reassessments to be conducted in accordance with the adaptive design element of the trial or otherwise collect additional clinical data from the URIROX-2 or other clinical trials prior to submitting a BLA for reloxaliase; risks associated with Allena’s ability to enroll a sufficient number of patients to adequately power URIROX-2 in order to achieve ultimate statistical success for kidney stone disease progression in the long-term follow-up phase of the trial; risks related to Allena’s use of UOx and/or POx as surrogate endpoints in its ongoing clinical trials, neither of which it believes have been previously utilized as biomarkers to support regulatory approval of other drug candidates, and the risks related to validating that reductions in UOx and/or POx correlate with meaningful clinical benefit; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with Allena’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risk associated with Allena’s financial condition and its need to obtain additional funding to support its business activities, including the future clinical development of reloxaliase; and risks associated with Allena’s dependence on third parties. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Allena’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Item 1A of Part II of Allena’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, as well as discussions of potential risks, uncertainties and other important factors in Allena’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Allena undertakes no duty to update this information unless required by law.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Investor Contact

Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media Contact

Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

Whitestone Hosts its 6th Annual Christmas Tree Lighting and Hot Cocoa Stroll Event at Market Street at DC Ranch

HOUSTON, Dec. 04, 2019 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE:WSR) (“Whitestone” or the “Company”) kicks off the holiday season on Thursday, December 5th with the 6th Annual Christmas Tree Lighting and Hot Cocoa Stroll Event from 5:30pm to 8:00pm at its Market Street at DC Ranch property in Scottsdale, Arizona.

The Annual Tree Lighting Ceremony at the DC Ranch property has grown enormously since its beginning in 2014 and is now the formal holiday season kick-off celebration for the DC Ranch community. The event begins with the Hot Cocoa Stroll and will feature special performances through the night by Copper Ridge Middle School Orchestra, Blazer Band and Chorus, Desert Bells International, Dickens Carolers, and our popular dance troupe from the DC Dance AZ Studio.

The opening parade starts promptly at 5:30pm, led by Ralphie the Wayward Reindeer, Frosty the Snowman, and all of the Middle School performers and entertainers, ending with Santa arriving on a truck of the Scottsdale Fire Department with an escort of the Scottsdale Police Department.

Joining Santa and his merry friends will be local fan favorites the Lighted Stilt Walkers, the BOOM Percussion Group, and our Friendly Grinch! The public is invited to be our guests and stroll the magical street throughout the evening and enjoy holiday treats provided by Market Street at DC Ranch retailers and restaurants, arts & crafts stations, music, giveaways and more.   

Mr. Mastandrea commented, “Being a part of the local community is very important to us at Whitestone and we look forward to this event every year. We always get a huge turnout from the families in the surrounding community. It gives everyone an opportunity to enjoy our wonderful restaurants which offer a variety of specialties including; Flemings upscale steakhouse; our newest Italian restaurant Vic and Ola’s; our family-style Mexican restaurant Jalapeno Inferno; our American-style tavern and smokehouse Liberty Station; our sports-themed All American Modern Sports Grill; Grimaldi’s Coal Brick-Oven Pizza; The Herb Box; The Living Room wine café and lounge; and breakfast favorite Eggstasy.”

Mr. Mastandrea concluded, “We want to wish everybody a Merry Christmas from the Whitestone family, and a happy, safe, and prosperous New Year.”


About Whitestone REIT


Whitestone is a community-centered retail REIT that acquires, owns, manages, develops and redevelops high quality “e-commerce resistant” neighborhood, community and lifestyle retail centers principally located in the largest, fastest-growing and most affluent markets in the Sunbelt. Whitestone’s optimal mix of national, regional and local tenants provides daily necessities, needed services and entertainment to the communities in which they are located. Whitestone’s properties are primarily located in business-friendly Phoenix, Austin, Dallas-Fort Worth, Houston and San Antonio, which are among the fastest growing U.S. population centers with highly educated workforces, high household incomes and strong job growth. For additional information, visit www.whitestonereit.com.


Whitestone REIT Contact:


Kevin Reed, Director of Investor Relations
Whitestone REIT
(713) 435-2219
ir@whitestonereit.com

Vonage to Present at the UBS Global TMT Conference

PR Newswire

HOLMDEL, N.J., Dec. 4, 2019 /PRNewswire/ — Vonage Holdings Corp. (NYSE: VG), a business cloud communications leader, today announced that management is scheduled to present at the UBS Global TMT Conference in New York. The presentation will begin at 10:45 a.m. ET on Tuesday, December 10, 2019.

New Vonage logo (PRNewsfoto/Vonage)

A live webcast of the event will be available on Vonage’s Investor Relations website. A replay will be available shortly after the live webcast.

About Vonage

Vonage (NYSE:VG) is redefining business communications once again. We’re making communications more flexible, intelligent, and personal, to help enterprises the world over, stay ahead. We provide unified communications, contact centers and programmable communications APIs, built on the world’s most flexible cloud communications platform. True to our roots as a technology disruptor, our flexible approach helps us to better serve the growing collaboration, communications, and customer experience needs of companies, across all communications channels.

Vonage Holdings Corp. is headquartered in New Jersey, with offices throughout the United States, Europe, Israel, Australia and Asia. To follow Vonage on Twitter, please visit www.twitter.com/vonage. To become a fan on Facebook, go to www.facebook.com/vonage. To subscribe on YouTube, visit www.youtube.com/vonage.

(vg-f)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/vonage-to-present-at-the-ubs-global-tmt-conference-300969434.html

SOURCE Vonage

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Vivint Solar, Inc. and Encourages Investors to Contact the Firm

PR Newswire

NEW YORK, Dec. 4, 2019 /PRNewswire/ — Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of investors that purchased Vivint Solar, Inc. (NYSE: VSLR) securities between March 5, 2019 and September 26, 2019 (the “Class Period”).  Investors have until December 10, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

(PRNewsfoto/Bragar Eagel & Squire, P.C.)

Click here to participate in the action.

On September 27, 2019, Marcus Aurelius Value published a report alleging that “28 undisclosed lawsuits . . . specifically allege Vivint forged customer contracts or otherwise engaged in fraud or deception.”

On this news, the company’s share price fell $0.14 per share, or over 2%, to close at $6.55 per share on September 27, 2019.

The complaint, filed on October 11, 2019, alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the company engaged in fraudulent practices, including forging customer contracts; (2) that, as a result, the company’s reported sales and megawatts installed were overstated; (3) that these practices were reasonably likely to lead to regulatory scrutiny: (4) that, as a result, the company’s earnings would be materially and adversely impacted; and (5) that, as a result of the foregoing, defendants’ positive statements about the company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

If you purchased Vivint Solar securities during the Class Period, continue to hold shares purchased before the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes. 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/deadline-alert-bragar-eagel–squire-pc-reminds-investors-that-a-class-action-lawsuit-has-been-filed-against-vivint-solar-inc-and-encourages-investors-to-contact-the-firm-300969456.html

SOURCE Bragar Eagel & Squire, P.C.